Price T Rowe Associates Inc. MD Sells 365,762 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Price T Rowe Associates Inc. MD reduced its position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 96.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,182 shares of the company's stock after selling 365,762 shares during the period. Price T Rowe Associates Inc. MD's holdings in Black Diamond Therapeutics were worth $31,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BDTX. Intech Investment Management LLC boosted its stake in shares of Black Diamond Therapeutics by 49.1% in the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company's stock valued at $41,000 after purchasing an additional 6,340 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Black Diamond Therapeutics by 429.6% in the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock valued at $41,000 after purchasing an additional 15,355 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Black Diamond Therapeutics in the fourth quarter valued at approximately $42,000. Wells Fargo & Company MN grew its stake in shares of Black Diamond Therapeutics by 41.8% during the fourth quarter. Wells Fargo & Company MN now owns 20,119 shares of the company's stock worth $43,000 after buying an additional 5,932 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in shares of Black Diamond Therapeutics during the fourth quarter worth $49,000. 95.47% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BDTX has been the subject of a number of research reports. HC Wainwright increased their price target on Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, March 18th. Wall Street Zen raised Black Diamond Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday. Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th. Finally, Stifel Nicolaus reduced their price target on Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $14.60.

Black Diamond Therapeutics Price Performance

Shares of Black Diamond Therapeutics stock traded up $0.03 during trading on Thursday, hitting $2.06. The company's stock had a trading volume of 759,577 shares, compared to its average volume of 1,495,443. The stock has a market cap of $117.14 million, a price-to-earnings ratio of -1.55 and a beta of 2.63. Black Diamond Therapeutics, Inc. has a 52 week low of $1.20 and a 52 week high of $6.75. The stock has a 50-day moving average price of $1.62 and a two-hundred day moving average price of $2.11.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.03. On average, equities analysts predict that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current fiscal year.

Insider Buying and Selling

In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the company's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the sale, the insider now owns 2,733,547 shares of the company's stock, valued at approximately $5,658,442.29. This represents a 67.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.87% of the stock is owned by insiders.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.